GSK PLC Sponsored ADR $GSK Shares Sold by First Bank & Trust

Key Points

• First Bank & Trust cut its GSK stake by 63.2% in the third quarter, selling 26,228 shares and retaining 15,291 shares valued at approximately $737,000. Institutional investors collectively own 15.74% of GSK.
• GSK reported quarterly EPS of $1.36, beating estimates by $0.09, while revenue rose 5.3% year over year to $11.14 billion. The company projected fiscal 2026 EPS of $4.90–$5.00.
• GSK raised its quarterly dividend to $0.4515 per share, equivalent to a 3.6% annualized yield. Analysts maintain a consensus “Hold” rating, with an average price target of $55.33 versus the stock’s $49.54 opening price.

First Bank & Trust decreased its holdings in shares of GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 63.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 15,291 shares of the pharmaceutical company's stock after selling 26,228 shares during the quarter. First Bank & Trust's holdings in GSK were worth $737,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Security National Bank of SO Dak purchased a new stake in GSK in the second quarter valued at approximately $38,000. Trust Co. of Vermont acquired a new position in GSK during the second quarter worth $54,000. Philadelphia Investment Partners LLC acquired a new position in GSK during the second quarter worth $70,000. Ancora Advisors LLC purchased a new position in shares of GSK during the second quarter worth $71,000. Finally, Bogart Wealth LLC boosted its position in shares of GSK by 15.3% during the first quarter. Bogart Wealth LLC now owns 1,508 shares of the pharmaceutical company's stock worth $83,000 after buying an additional 200 shares during the period. Hedge funds and other institutional investors own 15.74% of the company's stock.

GSK Stock Performance

Shares of GSK stock opened at $49.54 on Monday. The stock's 50-day moving average is $49.61 and its two-hundred day moving average is $51.62. The company has a debt-to-equity ratio of 0.81, a quick ratio of 0.52 and a current ratio of 0.82. GSK PLC Sponsored ADR has a 1 year low of $42.85 and a 1 year high of $61.69. The firm has a market cap of $100.21 billion, a price-to-earnings ratio of 15.49, a PEG ratio of 2.23 and a beta of 0.33.

GSK (NYSE:GSK - Get Free Report) last announced its earnings results on Tuesday, July 28th. The pharmaceutical company reported $1.36 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.27 by $0.09. The business had revenue of $11.14 billion for the quarter, compared to analyst estimates of $11.02 billion. GSK had a net margin of 14.56% and a return on equity of 43.23%. The company's revenue for the quarter was up 5.3% compared to the same quarter last year. During the same period last year, the firm posted $0.47 earnings per share. GSK has set its FY 2026 guidance at 4.900-5.000 EPS. Analysts predict that GSK PLC Sponsored ADR will post 4.78 earnings per share for the current year.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, October 8th. Shareholders of record on Friday, August 14th were given a dividend of $0.4515 per share. This represents a $1.81 annualized dividend and a yield of 3.6%. The ex-dividend date of this dividend was Friday, August 14th. This is an increase from GSK's previous quarterly dividend of $0.44. GSK's payout ratio is 55.31%.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. Citigroup initiated coverage on GSK in a research note on Friday, July 24th. They set a "neutral" rating on the stock. Berenberg Bank reaffirmed a "buy" rating on shares of GSK in a research report on Tuesday, October 6th. Wolfe Research assumed coverage on shares of GSK in a research note on Friday, October 9th. They set an "outperform" rating and a $70.00 price target on the stock. Jefferies Financial Group reiterated a "buy" rating on shares of GSK in a research note on Monday, September 28th. Finally, Wall Street Zen cut shares of GSK from a "buy" rating to a "hold" rating in a research report on Saturday, August 1st. Four investment analysts have rated the stock with a Buy rating, twelve have given a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $55.33.

About GSK

GSK plc, formerly GlaxoSmithKline, is a global biopharmaceutical company headquartered in Brentford, England. The company focuses on researching, developing and commercializing medicines and vaccines designed to prevent and treat infectious diseases, respiratory conditions, immune-related disorders and certain cancers.

Its vaccine portfolio includes products such as Shingrix for shingles, Arexvy for respiratory syncytial virus (RSV) in older adults, and vaccines targeting meningitis, influenza and other infectious diseases.

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GSK PLC Sponsored ADR (NYSE:GSK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.